首页 | 本学科首页   官方微博 | 高级检索  
检索        

复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析
引用本文:段雪琳,黎桂玉,李树民,彭岳,赵铁建.复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析[J].中国医院药学杂志,2015,35(19):1762-1765.
作者姓名:段雪琳  黎桂玉  李树民  彭岳  赵铁建
作者单位:1. 广西中医药大学基础医学院, 广西 南宁 530001; 2. 广西中医药大学研究生学院, 广西 南宁 530200
基金项目:国家自然科学基金项目(编号:81160553、81260675);广西科学研究与技术开发计划基金项目(编号:桂科攻13349005);广西研究生教育创新计划基金项目(编号:JGY2014082)
摘    要:目的:系统评价复方鳖甲软肝片联合恩替卡韦及单用恩替卡韦对慢性乙型肝炎血清肝纤维化四项指标的影响。方法:计算机检索中国期刊全文数据库(CNKI)、中文科技期刊数据库(VIP)、万方数据资源系统(WANFANG DATA)、中国生物医学文献数据库(CBM)以及英文数据库PubMed、Embase、Web of Science、the Cochrane Library,检索自建库至2015年1月以来复方鳖甲软肝片联合恩替卡韦与单用恩替卡韦治疗慢性乙型肝炎的临床随机对照试验。按纳入和排除标准筛选文献,再进一步提取及分析资料,采用RevMan 5.3软件对多个临床试验结果的总体效应进行Meta分析。结果:共纳入7个临床随机对照试验,共539例患者,观察组272例,对照组267例,均为慢性乙型肝炎治疗的研究。复方鳖甲软肝片联合观察组血清肝纤维化四项指标即透明质酸(HA),层粘连蛋白(LN),Ⅲ型前胶原蛋白(PCⅢ)、Ⅳ型胶原蛋白(IV-C)水平均较单用恩替卡韦组显著降低(P<0.05)。结论:复方鳖甲软肝片联合恩替卡韦能明显降低慢性乙型肝炎血清肝纤维化指标,但由于目前研究质量偏低,尚需要大量、严格、方法学质量高的随机对照试验进一步证实。

关 键 词:复方鳖甲软肝片  恩替卡韦  慢性乙型肝炎  血清肝纤维化标志物  Meta分析  
收稿时间:2015-02-27

Meta-analysis of influences of Fufang Biejia Ruangan Pian combined with entecavir on serum liver fibrosis markers of chronic hepatitis B
DUAN Xue-lin,LI Gui-yu,LI Shu-min,PENG Yue,ZHAO Tie-jian.Meta-analysis of influences of Fufang Biejia Ruangan Pian combined with entecavir on serum liver fibrosis markers of chronic hepatitis B[J].Chinese Journal of Hospital Pharmacy,2015,35(19):1762-1765.
Authors:DUAN Xue-lin  LI Gui-yu  LI Shu-min  PENG Yue  ZHAO Tie-jian
Institution:1. Department of Physiology, School of Basic Medicine, Guangxi University of Traditional Chinese Medicine, Guangxi Nanning 530001, China; 2. Graduate School of Guangxi University of Traditional Chinese Medicine, Guangxi Nanning 530200, China
Abstract:OBJECTIVE To evaluate effects of Fufang Biejia Ruangan Pian combined with entecavir and entecavir alone on four serum liver fibrosis markers of chronic hepatitis B. METHODS CNKI, VIP, WANFANG DATA, CBM, PubMed, Embase, Web of Science, and Cochrane Library were searched from inception to January 2015 to collect Fufang Biejia Ruangan Pian combined with entecavir and entecavir alone against chronic hepatitis B: randomized controlled trials. Inclusion and exclusion criteria were used to screen the trials. Data were extracted and analyzed by RevMan 5.3 software to Meta analyze overall effects of multiple clinical test results. RESULTS Seven randomized controlled trials were included, including 539 patients in total, 272 in observation group and 267 in control group. Four serum liver fibrosis indicators, including hyaluronic acid (HA), laminin (LN), type III procollagen (PC III), type IV collagen protein (IV-C) levels, decreased significantly in patients receiving Fufang Biejia Ruangan Pian combined with entecavir compared with those receiving entecavir alone (P<0.05). CONCLUSION Fufang Biejia Ruangan Pian combined with entecavir can significantly decrease serum indexes of liver fibrosis of chronic hepatitis B. However, quality of current research is low, randomized controlled trials with large sample, strict and high quality of methodology are still needed to verify these results.
Keywords:Fufang Biejia Ruangan Pian  entecavir  chronic hepatitis B  liver fibrosis markers in serum  Meta analysis  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号